Common Contracts

Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Asset Purchase Agreement • August 8th, 2024 • 2seventy Bio, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  August 8th, 2024
• Company
  2seventy Bio, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of June 21, 2024, is made by and between 2seventy bio, Inc., a Delaware corporation (“Seller”), and Novo Nordisk A/S, a Danish corporation (“Buyer”).

ASSET PURCHASE AGREEMENT BY AND BETWEEN 2SEVENTY BIO, INC. AND REGENERON PHARMACEUTICALS, INC. DATED AS OF January 29, 2024

Asset Purchase Agreement • May 9th, 2024 • 2seventy Bio, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  May 9th, 2024
• Company
  2seventy Bio, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of January 29, 2024, is made by and between 2seventy bio, Inc., a Delaware corporation (“Seller”), and Regeneron Pharmaceuticals, Inc., a New York corporation (“Buyer”).